• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Top Rated Providers for Medicare Prescription Health Plans in 2024

News
Article

Each state’s best insurance company.

The Center for Medicare and Medicaid Services (CMS) released proposed payment updates for 2025 Medicare Advantage and Part D programs in November.

There are four parts of Medicare coverage: Part A, Part B, Part C and Part D.

Part A provides hospital coverage, Part B provides outpatient coverage, Part C is Medicare Advantage, which allows private insurance companies to provide services and Part D covers prescription costs.

Starting in 2025, Medicare beneficiaries enrolled in Part D programs will have their prescription costs capped at $2,000, potentially saving money for more than 1 million enrollees.

Here are the top-rated providers for prescription drug costs in each state, as reported by U.S. News.

The states marked with an asterisk are considered the U.S. New and World Report’s top insurance companies. States received this ranking from the CMS and were rated at least three out of five stars and had an average rating of 4.0 or more stars within the state.

Related Videos
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Video 8 - "Risk and Value-Based Contracting for Prescription Drug Therapeutics and Manufacturer’s Support in Utilization"
Video 7 - "Prescribing Prescription Drug Therapeutics: Factors for Providers and Payers to Consider"
Video 9 -"Overcoming Implementation Barriers for Digital Therapeutics Adoption"
© 2024 MJH Life Sciences

All rights reserved.